Entasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021
Entasis Therapeutics Holdings announced it will disclose its third quarter 2021 financial results on November 4, 2021, before market opening.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Entasis Therapeutics Holdings announced it will disclose its third quarter 2021 financial results on November 4, 2021, before market opening. A conference call and webcast will take place at 8:00 AM ET to discuss the results and provide updates on clinical and corporate matters, followed by a Q&A session. Investors can access the call by phone or through a provided link. Entasis focuses on developing innovative antibacterial products targeting serious infections from multidrug-resistant Gram-negative bacteria, with a pipeline that includes several advanced candidates.
Details
News Market Reaction – ETTX
The recorded move for ETTX in the trading session of this news was +3.36%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report third quarter 2021 financial results before the market opens on November 4, 2021. The company will host a conference call and webcast at 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. A question-and-answer session will follow management’s prepared remarks.
Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes prior to the start of the call by dialing 888-394-8218 (U.S.) or 323-701-0225 (international) or through the link Entasis Therapeutics Third Quarter 2021 Earnings Conference Call. A replay of the call will be available from the Entasis website at www.entasistx.com following the call.
About Entasis
Entasis is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including post Phase 3 sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0462 (targeting multiple Gram-negative pathogens including Pseudomonas aeruginosa) and ETX0282CPDP (targeting Enterobacteriaceae infections). For more information, visit www.entasistx.com.
| Entasis Contacts | |
| Company Contact | Investor Contact |
| Kyle Dow | Bruce Mackle |
| Entasis Therapeutics | LifeSci Advisors |
| (781) 810-0114 | (929) 469-3859 |
| kyle.dow@entasistx.com | bmackle@lifesciadvisors.com |
| Media Contact | |
| Brett Whelan | |
| LifeSci Communications | |
| (215) 315 3143 | |
| bwhelan@lifescicomms.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.